공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

위염 : 파이프라인 리뷰

Gastritis (Gastrointestinal) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 360905
페이지 정보 영문 99 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


위염 : 파이프라인 리뷰 Gastritis (Gastrointestinal) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 99 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

위염(Gastritis) 치료제의 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 치료제 개발에 참여하고 있는 주요 기업 및 약제 개요, 최신 파이프라인 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

위염 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 기업에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • BCWorld Pharm Co Ltd
  • Boryung Pharmaceutical Co Ltd
  • Daewon Pharm Co Ltd
  • Recce Ltd
  • RedHill Biopharma Ltd

약제 개요

위염 : 휴지중인 프로젝트

위염 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.08.17

List of Tables

List of Tables

  • Number of Products under Development for Gastritis, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Gastritis - Pipeline by Addpharma Inc, 2021
  • Gastritis - Pipeline by Allakos Inc, 2021
  • Gastritis - Pipeline by CalyGene Biotechnology Inc, 2021
  • Gastritis - Pipeline by Daewon Pharmaceutical Co Ltd, 2021
  • Gastritis - Pipeline by GNT Pharma Co Ltd, 2021
  • Gastritis - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
  • Gastritis - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2021
  • Gastritis - Pipeline by Kyowa Kirin Co Ltd, 2021
  • Gastritis - Pipeline by Marinomed Biotech AG, 2021
  • Gastritis - Pipeline by Otsuka Holdings Co Ltd, 2021
  • Gastritis - Pipeline by Recce Pharmaceuticals Ltd, 2021
  • Gastritis - Pipeline by RedHill Biopharma Ltd, 2021
  • Gastritis - Pipeline by Trio Medicines Ltd, 2021
  • Gastritis - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Gastritis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Drugs In Development, 2021, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastritis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Gastritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gastritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 2, 5 and 1 respectively.

Gastritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastritis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastritis (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastritis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Gastritis - Overview
  • Gastritis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Gastritis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Gastritis - Companies Involved in Therapeutics Development
  • Addpharma Inc
  • Allakos Inc
  • CalyGene Biotechnology Inc
  • Daewon Pharmaceutical Co Ltd
  • GNT Pharma Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Kukje Pharmaceutical Industry Co Ltd
  • Kyowa Kirin Co Ltd
  • Marinomed Biotech AG
  • Otsuka Holdings Co Ltd
  • Recce Pharmaceuticals Ltd
  • RedHill Biopharma Ltd
  • Trio Medicines Ltd
  • Gastritis - Drug Profiles
  • AAD-2004 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AD-206 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • benralizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CG-20043 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DW-1903 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HIP-2101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INT-2150 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lirentelimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MAM-20101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ND-07 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • netazepide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ondansetron hydrochloride CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rebamipide ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rebamipide SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RECCE-327 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RECCE-435 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gastritis - Dormant Projects
  • Gastritis - Product Development Milestones
  • Featured News & Press Releases
  • Jun 07, 2021: Allakos completes patient enrollment in phase 3 eosinophilic gastritis and/or eosinophilic duodenitis and phase 2/3 eosinophilic esophagitis clinical trials of lirentelimab (AK002)
  • Dec 08, 2020: Rebamipid, which has risen in price, imminent commercialization of domestically developed western-release tablets
  • Oct 26, 2020: Results from prospective prevalence study indicate that eosinophilic gastritis and eosinophilic duodenitis may be significantly underdiagnosed
  • Oct 26, 2020: Allakos announces results from a phase 1 study of subcutaneously administered lirentelimab (AK002)
  • Oct 21, 2020: Anti-Siglec-8 Antibody trial shows promise for treating Eosinophilic gastritis and duodenitis
  • Oct 21, 2020: Allakos announces publication of results from the phase 2 study of lirentelimab (AK002) in patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
  • Jun 03, 2020: Allakos initiates patient recruitment for AK002 registrational studies
  • May 04, 2020: Allakos announces positive interim results from an open-label extension study of Antolimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis
  • Apr 21, 2020: Allakos announces multiple presentations related to eosinophil and mast cell-driven diseases at the 2020 DDW Annual Meeting
  • Mar 24, 2020: Allakos announces positive phase 1 results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease
  • Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
  • Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)
  • Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestinal diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
  • Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
  • Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q